Euroscreen FAST now offers the possibility to develop and test internalization assays for your GPCR of interest.
Receptor internalization after agonist binding and signal transduction is a feature of many GPCR, leading to degradation and long-term desensitization, or recycling to the cell surface for the next round of stimulation. This important phenomenon needs to be addressed in Drug Discovery programs as it can lead either to therapeutic or adverse effects. Moreover, as this event is independent of the exact nature of G-protein coupling, it is particularly suited to study orphan receptors for which there is little-to-no information about their physiological signaling cascades.
Using the TagLite technology, Euroscreen has now added a brand new line of internalization assays to its already extensive GPCR testing catalogue. Targets currently available include GPR84, GIP, human and mouse GLP-1, GPR17 and GPR55. New assays will be added regularly but we can also perform custom assay development for a soft budget and with a fast turn-around-time.
Le Ministère Français de l'Education Nationale, de l'Enseignement Supérieur et de la Recherche délivre à Euroscreen un agrément pour Dépenses de Recherche couvrant les années 2014-2015-2016. Ceci permet à tous nos clients français de bénéficier d'une réduction d'impôt sur les dépenses de recherche engagées dans notre service.
Euroscreen collaborates with Novartis on successful GPR15 deorphanization
Euroscreen offers a one-of-a-kind GPCR deorphanization platform and has a unique track record in this highly challenging field with 17 successes during these past 20 years. The latest addition to this list is the identification of the natural ligand for the GPR15 receptor, in collaboration with Novartis.
Euroscreen’s deorphanization platform offers to our clients a diverse and flexible panel of cellular and screening tools and a proprietary library of tissue extracts, allowing the identification of natural ligand for GPCRs.